Printer Friendly

Eisai Seeks Approval to Market Pariet(R) Triple Formulation Pack in Japan for Helicobacter Pylori Eradication.

Tokyo, May 31, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application to Japan's Ministry of Health, Labour and Welfare seeking approval for two types of new triple formulation packs (combination packs) for Helicobacter Pylori eradication that include the company's proton pump inhibitor Pariet(R) (rabeprazole sodium) as well as amoxicillin hydrate (generic name) and either clarithromycin (generic name) for primary eradication or metronidazole (generic name) for secondary eradication.

Pariet was approved in Japan in January 2007 for adjunctive use with amoxicillin hydrate and clarithromycin in the eradication (primary eradication) of Helicobacter Pylori infections associated with gastric and duodenal ulcers. In August of the same year, the agent was also approved for secondary eradication, in combination with amoxicillin and metronidazole, in patients for whom primary eradication therapy has been unsuccessful. Additionally, the eradication therapy indication for Pariet was expanded in June 2010 to include gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and the stomach after endoscopic resection of early stage gastric cancer.

During eradication therapy consisting of Pariet and two antimicrobial agents, the success of therapy depends on whether or not patients properly adhere to the prescribed treatment regimen. If patients take the wrong medication or forget to take their medication altogether, this leads not only to a reduction in eradication rates but can also result in problems such as bacterial resistance and an increase in side effects. Eisai has developed the new triple formulation pack for primary and secondary eradication that includes three separate formulations in a single package in order to help ensure that eradication therapy will be carried out more appropriately and with greater certainty, improve patient drug compliance and offer increased levels of convenience in the medical setting.

Eisai firmly believes that the newly developed triple formulation pack will help facilitate the proper use of drugs during Helicobacter pylori eradication and will thereby further contribute to increasing patient benefits.

Please refer to for further information on Pariet/Aciphex, currently approved dosage and administration for Pariet as an adjunctive therapy for Helicobacter Pylori eradication, and an outline of the triple formulation pack.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Source: Eisai

Public Relations Department,
Eisai Co., Ltd.

Copyright 2011 JCN Newswire. All rights reserved.
COPYRIGHT 2012 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:May 31, 2012
Previous Article:Cumulative Toyota Production in Taiwan Tops 2 Million Mark.
Next Article:Fujitsu Laboratories Develops Technology for Compact Optical Transceivers that Double Data Transmission Speeds to 25 Gbps.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters